Remotely Monitored, Mobile Health-supported, High Intensity Interval Training Before Hematopoietic Stem Cell Transplant
Launched by UNIVERSITY OF KANSAS MEDICAL CENTER · Apr 23, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how a special exercise program called REMM-HIIT, which is monitored remotely, can improve fitness and physical abilities in patients who are about to undergo stem cell transplantation. The main questions researchers want to answer are whether this training helps participants get fitter and feel better physically. Participants in the study will be compared to a control group who won’t do the training to see if the exercise program makes a difference in their recovery after transplant.
To be eligible for this trial, participants need to be between 18 and 80 years old and planning to have a stem cell transplant in the next 4 to 12 weeks. They should be comfortable reading and writing in English and able to follow exercise coaching. Throughout the study, participants will complete various fitness tests, track their daily activity, and may even provide samples of blood and stool. This study is not yet recruiting, but it aims to help understand how exercise can support patients during a critical time in their treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Plan to undergo allogeneic hematopoietic stem cell transplant in 4-12 weeks after enrollment on this study.
- • Age 18-80 years
- • Able to read/write English (as many participant-reported outcome measures lack validated translations in other languages)
- Exclusion Criteria:
- • Unable or unwilling to follow coaching
- • Functional impairment resulting in inability to exercise
- * Any absolute contraindications to exercise:
- • 1. recent (\<6 months) acute cardiac event;
- • 2. unstable angina;
- • 3. uncontrolled dysrhythmias causing symptoms;
- • 4. symptomatic aortic stenosis;
- • 5. uncontrolled symptomatic heart failure;
- • 6. acute pulmonary embolus;
- • 7. acute myocarditis or pericarditis;
- • 8. suspected or known dissecting aneurysm
About University Of Kansas Medical Center
The University of Kansas Medical Center (KUMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research, education, and clinical practice. As a prominent clinical trial sponsor, KUMC leverages its extensive expertise in diverse medical fields to conduct rigorous clinical research aimed at improving patient outcomes and developing new treatment modalities. With a commitment to ethical standards and patient safety, KUMC collaborates with multidisciplinary teams to facilitate groundbreaking studies that address significant health challenges, ultimately contributing to the advancement of medical knowledge and the enhancement of community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Kansas City, Kansas, United States
Houston, Texas, United States
Patients applied
Trial Officials
Anthony Sung, MD
Principal Investigator
The University of Kansas Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported